|
|
 |
|
Viewing report
|
|
|
|
New Approaches to Pharma R&D: Evolving Strategies to Rejuvenate R&D Efficiency
Datamonitor, May 2009, Pages: 79
With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
- Overview of ongoing trends affecting R&D and how these will shape Pharma in the future
- R&D Insight from Big Pharma industry executives
- Analysis into Pharmas evolving R&D portfolio between 2006 and 2009, in addition to examination of pipeline M&A and collaborative deals
- Case studies of innovative strategies used to maximize R&D productivity
GlaxoSmithKline, Pfizer and AstraZeneca have the largest preclinical and clinical drug pipelines, each with approximately 200 candidates in development as of March 2009. In terms of volume growth Genentechs pipeline grew the most in terms of percentage points, almost doubling (up 95%).
Over the period 200609, the average growth per therapy area was 9.4%. In terms of percentage points, the therapy area experiencing the largest growth in pipeline candidates was ophthalmology, while cardiovascular pipelines saw the largest decline, indicative of Pharmas shift towards niche markets and personalized medicines.
The number of pipeline deals made during 200608 have steadily declined. However, with Biotech finding it hard to fund R&D at present, and with many companies going bankrupt, this will affect Big Pharma in the longer term, which is increasingly downsizing internal research becoming ever reliant on external sources.
- Identify R&D trends in todays pharmaceutical market, and how these affect productivity and return on investment
- Understand how a diverse range of strategies can improve R&D productivity and output, and identify how these can best be implemented
- Gain insight into how to optimize R&D processes and increase the chance of clinical, and ultimately commercial success
Customers who bought this item also bought
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Allergy Drug Pipeline and R&D 2009
Allergy Drug Pipeline and R&D 2009
Bio/Pharma R&D Statistical Sourcebook 2008/2009
What to Do When the R&D Pipeline Runs Dry
The Pharma R&D Fact Book 2007
Innovative Drug R&D in China
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus on Leukemias and Lymphomas
Constipation Therapy Area Pipeline Report
Hypogonadism Therapy Area Pipeline Report
Alcoholism Therapy Area Pipeline Report
|
|
|
|
